# Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

> **NCT00875394** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 68 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** sitagliptin phosphate
- **DRUG:** Comparator: metformin
- **DRUG:** Comparator: metformin
- **DRUG:** Comparator: Antidiabetic Standard of Care

## Key facts

- **NCT ID:** NCT00875394
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-01
- **Primary completion:** 2008-06-27
- **Final completion:** 2008-06-27
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00875394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00875394, "Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00875394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*